Incannex Healthcare Limited (IXHL) Joel Latham, CEO

Incannex is a clinical stage pharmaceutical development company that isdeveloping unique medicinal cannabinoid pharmaceutical products and psychedelicmedicine therapies for the treatment of anxiety disorders, obstructive sleepapnoea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation (ARDS,COPD, asthma, bronchitis), rheumatoid arthritis and inflammatory bowel disease.U.S. FDA approval and registration, subject to ongoing clinical success, isbeing pursued for each drug and therapy under development. Each indicationrepresents major global markets and currently have no, or limited, existingregistered pharmacotherapy (drug) treatments available to the public.